Unicycive Therapeutics Inc. (NASDAQ:UNCY) finished Wednesday with a subtraction of -$0.17 to close at $0.50, a downside of -25.37 percent. An average of 1,790,980 shares of common stock have been traded in the last five days. There was a fall of -$0.1900 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 473,460 shares traded, while the 50-day average volume stands at 210,178.
UNCY stock has decreased by -24.24% in the last month. The company shares reached their 1-month lowest point of $0.4005 on 12/28/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.51 and a high of $2.35 in 52 weeks. It has reached a new high 1 time so far this year and lost -75.73% or -$1.5600 in price. In spite of this, the price is down -78.72% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Unicycive Therapeutics Inc. (UNCY) has a trailing price-to-sales (P/S) ratio at 7.99, the price-to-book (PB) ratio at 1.61.
The quick ratio of Unicycive Therapeutics Inc. for the three months ended September 29 was 1.80, and the current ratio was 1.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $0.63 million compared to revenue of $8.98 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Unicycive Therapeutics Inc.’s return on assets was -107.70%.
The company posted a net income of -$5.56 million in the quarter, while revenues of -$3.64 million were grew 6.47%. The analyst consensus anticipated Unicycive Therapeutics Inc.’s latest quarter earnings to come in at -$0.28 per share, but it turned out to be -$0.37, a -32.10% surprise. For the quarter, EBITDA amounted to -$5.51 million. Shareholders own equity worth $15.09 million.
From a technical analysis perspective, let’s take a brief look at Unicycive Therapeutics Inc. (UNCY) price momentum. RSI 9-day as of the close on 28 December was 17.85%, suggesting the stock is oversold, with historical volatility in this time frame at 145.61%.
As of today, UNCY’s price is $0.6577 -27.54% or -$0.1900 from its 5-day moving average. UNCY is currently trading -30.53% lower than its 20-day SMA and -32.43% lower than its 100-day SMA. However, the stock’s current price level is -16.67% below the SMA50 and -57.26% below the SMA200.
The stochastic %K and %D were 27.51% and 32.45%, respectively, and the average true range (ATR) was 0.1161. With the 14-day stochastic at 22.72% and the average true range at 0.0997, the RSI (14) stands at 26.00%. The stock has reached -0.0569 on the 9-day MACD Oscillator while the 14-day reading was at -0.0765.
The consensus rating for Unicycive Therapeutics Inc. (UNCY) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell UNCY, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.
What is UNCY’s price target for the next 12 months?
Analysts predict a range of price targets between $3.00 and $13.00, with a median target of $8.00. Taking a look at these predictions, the average price target given by analysts for Unicycive Therapeutics Inc. (UNCY) stock is $8.00.